PEGBIO CO-B (02565) showed robust performance today, with its share price rising as much as 18.91% intraday to HK$29.3. The trading volume reached HK$59.66 million. The surge follows the company's recent announcement that its cornerstone investors have voluntarily agreed not to reduce their holdings in any manner from the original lock-up expiration date of April 30 until May 20. The company views this extension as a reflection of the cornerstone investors' strong confidence in its future prospects, based on its capabilities in advancing technological R&D and achieving significant clinical milestones. Analysts have previously noted that PEGBIO is one of the few domestic enterprises capable of independently producing pharmaceutical-grade polyethylene glycol raw materials and integrating them into the full development process of chronic disease treatments. By focusing on the research and development of innovative molecular entities with novel targets, novel binding sites, and novel mechanisms of action, the company has built a diversified product pipeline that offers complementary mechanisms and combines clinical value with patient benefits.